Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Likmez in Pediatric Anaerobic Bacterial Infection
NCT07146217Phase 2Not yet recruiting
- Sponsor
- Saptalis Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metronidazole in anaerobic infection, sponsored by Saptalis Pharmaceuticals. Primary endpoints: Maximum plasma concentration at Day 1, Time to reach maximum plasma concentration at Day 1 and 3 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
metronidazole
03
Conditions
anaerobic infection
Beyond the preview
Go deeper on NCT07146217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146217.